This article is more than 5 years old. Information may no longer be current.
Prostaglandin analogues produce no significant differences in tolerability after 3 months
Click Here to Manage Email Alerts
Open-angle glaucoma and ocular hypertension patients treated for 3 months with prostaglandin analogues with different preservatives showed no significant differences in ocular surface tolerability, a study found.
The randomized, multicenter, investigator-masked study analyzed 164 patients for observable clinical differences in ocular surface tolerability related to preservatives. Benzalkonium chloride 0.02% is used in Lumigan (bimatoprost 0.01%, Allergan) and Xalatan (latanoprost 0.005%, Pfizer), and sofZia is used in Travatan Z (travoprost 0.004%, Alcon).
Patients were treated for at least 1 month with latanoprost and then randomized to once-daily treatments with one of the medications for 3 months, with follow-up visits at weeks 1, 4 and 12. Fifty-six patients received bimatoprost, 53 received travoprost and 55 received latanoprost. The primary outcome measure was physician-graded conjunctival hyperemia at week 12, and corneal staining and tear breakup time were also measured.
At baseline, the patients had no significant differences in hyperemia, corneal staining or tear breakup time.
At 1 week, hyperemia scores in patients who received travoprost rose from 0.49 at baseline to 0.69, on a scale from 0 to 3. Scores in patients who received bimatoprost rose from 0.48 to 0.52, while patients who received latanoprost had no change (P = .018). There were no significant differences in corneal staining or tear breakup time.
At 12 weeks, there were no significant differences in any of the three outcome measures, and the type of preservative did not result in observable differences in ocular surface tolerability, the study authors said. Adverse events were comparable among the groups.
Click Here to Manage Email Alerts